ArticleNeurosurgical review2022

Regorafenib for recurrent high-grade glioma: a unicentric retrospective analysis of feasibility, efficacy, and toxicity.

Hannes Treiber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.